140 related articles for article (PubMed ID: 23710914)
1. [Expression of BRCA1 and WWOX and their clinicopathologic implication in breast carcinomas occurring in young women].
Zhang QL; Zhang QH; Cong H; Zhang XL
Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):90-4. PubMed ID: 23710914
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
3. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.
Guler G; Huebner K; Himmetoglu C; Jimenez RE; Costinean S; Volinia S; Pilarski RT; Hayran M; Shapiro CL
Cancer; 2009 Feb; 115(4):899-908. PubMed ID: 19130459
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
[TBL] [Abstract][Full Text] [Related]
5. Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.
Mylona E; Melissaris S; Nomikos A; Theohari I; Giannopoulou I; Tzelepis K; Nakopoulou L
Pathol Res Pract; 2014 Aug; 210(8):533-40. PubMed ID: 24947414
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.
Zakhartseva LM; Gorovenko NG; Podolskaya SV; Anikusko NF; Lobanova OE; Pekur KA; Kropelnytskyi VA; Shurygina OV
Exp Oncol; 2009 Sep; 31(3):174-8. PubMed ID: 19877382
[TBL] [Abstract][Full Text] [Related]
7. [Expression of Ki67 and clinicopathological features in breast cancer].
Wang B; Wang X; Wang J; Xuan L; Wang Z; Wang X; Gao J; Zhang H
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):273-5. PubMed ID: 24989913
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
9. Frequent loss of BRCA1 nuclear expression in young women with breast cancer: an immunohistochemical study from an area of low incidence but early onset.
Lee WY
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):310-5. PubMed ID: 12607598
[TBL] [Abstract][Full Text] [Related]
10. [Expression and clinical significance of LRP16 gene in human breast cancer].
Liao DX; Han WD; Zhao YL; Pu YD; Mu YM; Luo CH; Li XH
Ai Zheng; 2006 Jul; 25(7):866-70. PubMed ID: 16831279
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas.
Aman NA; Doukoure B; Koffi KD; Koui BS; Traore ZC; Kouyate M; Toure I; Effi AB
Asian Pac J Cancer Prev; 2019 Jan; 20(1):73-79. PubMed ID: 30678383
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological study of chromogranin A, B and BRCA1 expression in node-negative breast carcinoma.
Yoshida R; Ohuchi N; Kimura N
Oncol Rep; 2002; 9(6):1363-7. PubMed ID: 12375049
[TBL] [Abstract][Full Text] [Related]
15. Invasive Ductal Carcinoma: Correlation of Immunophenotypic Features with Age.
Lateef F; Jamal S; Nasir S; Jamil Z
J Coll Physicians Surg Pak; 2017 Jan; 27(1):18-22. PubMed ID: 28292362
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
17. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters.
Lee WY; Jin YT; Chang TW; Lin PW; Su IJ
Histopathology; 1999 Feb; 34(2):106-12. PubMed ID: 10064388
[TBL] [Abstract][Full Text] [Related]
18. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
19. [Ki-67 expression and significance of different molecular subtypes of breast invasive ductal carcinoma].
Zhou SJ; Guo H
Zhonghua Yi Xue Za Zhi; 2013 Sep; 93(36):2895-7. PubMed ID: 24373403
[TBL] [Abstract][Full Text] [Related]
20. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
